Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study
Int J Urol
.
2022 May;29(5):476-478.
doi: 10.1111/iju.14817.
Epub 2022 Feb 7.
Authors
Toshikazu Tanaka
1
,
Shingo Hatakeyama
2
,
Daisuke Noro
3
,
Kyo Togashi
4
,
Takahiro Yoneyama
5
,
Chikara Ohyama
2
4
5
Affiliations
1
Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan.
2
Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
3
Department of Urology, Mutsu General Hospital, Mutsu, Japan.
4
Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
5
Department of, Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
PMID:
35132692
DOI:
10.1111/iju.14817
No abstract available
Publication types
Multicenter Study
Research Support, Non-U.S. Gov't
MeSH terms
Castration
Combined Modality Therapy
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / surgery
Retrospective Studies
Grants and funding
19H05556/Japan Society for the Promotion of Science
20K09517/Japan Society for the Promotion of Science